Rheumatoid Arthritis

Multimorbidity, the presence of multiple overlapping chronic comorbid conditions, is increasingly common at first presentation of rheumatoid arthritis (RA), increasing as a person gets older and/or…

Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical rheumatoid arthritis (RA) nor…

The COVID-19 pandemic has presented a global challenge. Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections. Over the past…

Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting. Study 144 pts Rx w/ Rituximab for Autoimmune renal Dz (AAV, FSGS, IgG4RD, LN, etc). 17% had Severe…

Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause…

CreakyJoints will present 11 posters and two oral presentations at ACR 2021. Data was derived from their large patient database and Arthritis Power Research Registry.  COVID-19 …

The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021.  Below is a listing of some of their best studies for you to…

The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021.  Below is a listing of some of their best studies for you to…

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that proactive therapeutic drug monitoring, a newer treatment strategy where a…

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like…